KEYTRUDA® (pembrolizumab) Receives New Draft Recommendation from National Institute for Health and Care Excellence (NICE) in U.K. for First-Line Treatment for Advanced Melanoma
October 09, 2015 at 07:00 AM EDT
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the National Institute for Health and Care ...
